INtravesical Antimicrobial Agents v STANDard Oral Antibiotics for the Treatment of Acute UTI in Women With rUTI

Overview

Información sobre este estudio

Women have problems with oral antibiotics, including vagina and bowel infections. Also, bacteria causing urinary infections are becoming more resistant to oral antibiotis. Placement of antibiotic directly into the bladder does not cause these problems and are at doses that are may be able to stop bacteria from being resistant to antibiotics.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

  • Ability to understand study procedures and to comply with them for the entire length of the study.

Exclusion Criteria:

  • Patients who report that they are pregnant.
  • Patients with a positive urine pregnancy test
  • Patients with a history of renal transplantation.
  • Patients with bladder augmentation procedures using bowel.
  • Patients with poorly controlled Type II diabetes, Hgb A1C >6.5%
  • Patients with spinal cord injury, ASIA Impairment Scale of C or higher.
  • Patients with pelvic surgery within 6 months.
  • Patients with urologic procedure within 6 months.
  • Patients with a history of reconstructive urologic surgery, such as reflux, congenital abnormality.
  • Immunocompromised patients being treated for malignancy or a history of actively treated malignancy within 5 years.
  • Patients with active systemic autoimmune disease.
  • Patients on systemic immunosuppression.
  • Use of antibiotic prophylaxis within 6 months
  • Use of antibiotics within 10 days of active infection
  • Allergy/sensitivity to gentamicin or nitrofurantoin.
  • Current drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.
  • Inability or unwillingness of individual to give written informed consent.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus

Rochester, Minn.

Investigador principal de Mayo Clinic

Deborah Lightner, M.D.

Cerrado para la inscripción

More information

Publicaciones

Publications are currently not available
.
CLS-20338633

Mayo Clinic Footer